Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study aims to explore a new, more effective and tolerable treatment regimen for patients
with advanced recurrent/metastatic nasopharyngeal carcinoma. Specifically, we plan to conduct
a phase III randomized controlled clinical trial based on the standard treatment of "GP +
PD-1 mAb", replacing cisplatin with apatinib to achieve "platinum-free" therapy and reduce
toxicity. In addition, we will investigate the efficacy of using apatinib in combination with
PD-1 mAb compared to PD-1 mAb monotherapy to further improve treatment outcomes. The ultimate
goal is to provide a new and reliable treatment modality for patients with advanced
recurrent/metastatic nasopharyngeal carcinoma and guide clinical practice.